Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
27 hedge funds and large institutions have $30.9M invested in Elevation Oncology in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
125% more capital invested
Capital invested by funds: $13.7M → $30.9M (+$17.2M)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
6.71% more ownership
Funds ownership: 61.91% → 68.62% (+6.7%)
0% more funds holding
Funds holding: 27 → 27 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.19M |
| 2 |
SCM
Sio Capital Management
New York
|
+$667K |
| 3 |
Walleye Capital
New York
|
+$561K |
| 4 |
Morgan Stanley
New York
|
+$191K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$274K |
| 2 |
Renaissance Technologies
New York
|
-$191K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$101K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$38K |
| 5 |
BlackRock
New York
|
-$6.18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $190 | -$2.17K | -1,682 | -94% |
|
27
Wells Fargo
San Francisco,
California
| $175 | +$3 | +2 | +2% |
|
|
TCM
28
TCG Crossover Management
Palo Alto,
California
| – | -$274K | -288,390 | Closed |
|
|
BCM
29
BML Capital Management
Zionsville,
Indiana
| – | -$38K | -39,963 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$1K | -842 | Closed |
|
|
SPIA
31
Steward Partners Investment Advisory
New York
| – | -$475 | -500 | Closed |
|
32
Barclays
London,
United Kingdom
| – | -$372 | -392 | Closed |
|
33
Bank of America
Charlotte,
North Carolina
| – | -$16 | -17 | Closed |
|
ELEV Hedge Fund Activity: Q1 2023 in Review
27 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q1 2023, worth a combined $30.9M — up 125% from $13.7M a quarter earlier.
Fund positioning in ELEV was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 4 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $1.19M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $274K sold.
- 27 institutional investors held Elevation Oncology (ELEV) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $30.9M of Elevation Oncology stock for Q1 2023, up 125% quarter-over-quarter.
- 6 funds opened new Elevation Oncology positions in Q1 2023 and 6 closed out, a net change of 0 holders.
- The largest Elevation Oncology buyer in Q1 2023 was Tang Capital Management, an estimated $1.19M added.
- The largest Elevation Oncology seller in Q1 2023 was TCG Crossover Management, an estimated $274K sold.
Based on aggregated 13F filings for Q1 2023.